Response to chemotherapy
. | FLAG, n (%) . | ARA-C + G-CSF, n (%) . |
|---|---|---|
| Total patients | 65 (100) | 69 (100) |
| Complete response | ||
| After induction cycle 1 | 41 (63) | 35 (51) |
| After cycles 1 and 2 | 46 (71) | 42 (61) |
| After cycles 1, 2, and 3 | 46 (71) | 45 (65) |
| No complete response | ||
| Early death | 2 (3) | 1 (1) |
| Death in hypoplasia | 7 (11) | 5 (7) |
| Resistance to chemotherapy | 8 (12) | 15 (22) |
. | FLAG, n (%) . | ARA-C + G-CSF, n (%) . |
|---|---|---|
| Total patients | 65 (100) | 69 (100) |
| Complete response | ||
| After induction cycle 1 | 41 (63) | 35 (51) |
| After cycles 1 and 2 | 46 (71) | 42 (61) |
| After cycles 1, 2, and 3 | 46 (71) | 45 (65) |
| No complete response | ||
| Early death | 2 (3) | 1 (1) |
| Death in hypoplasia | 7 (11) | 5 (7) |
| Resistance to chemotherapy | 8 (12) | 15 (22) |